On November 22, Enveda, a biotechnology company in Boulder, Colorado, that uses artificial intelligence to transform natural substances into new drugs, announced the completion of$130 Million Series C Financing,Led by Kinnevik and FPV, with participation from new and existing investors Baillie Gifford, Premji Invest, Lingotto Innovation, Lux Capital, Dimension Capital, True Ventures, Cresset Partners, The Nature Conservancy, and Henry R. Kravis. The company's total funding has reached $360 million.$230 Million Financing! Leveraging AI/ML to Develop New Drugs from Natural Sources）
The new funding will enable Enveda to deliver clinical catalysts through multiple programs with strong commercial potential by 2025 and 2026, continue advancing its deep pipeline of 10 development candidates and multiple discovery programs, and invest in its world-leading platform. This announcement follows the company's first clinical trial and the unveiling of a foundational metabolomics model trained on the world’s largest experimental mass spectrometry dataset.
Viswa Colluru, founder and CEO of Enveda, said:"Some of the greatest pharmaceutical breakthroughs in the world have come from just 0.1% of the chemical diversity of nature. We’ve built our platform to rapidly expand access to natural chemistry about four times faster to find cures, and it’s already delivering results in the form of a deep and differentiated pipeline. This funding will help us move multiple candidates into exciting clinical catalysts next year, validating our guiding vision that life’s chemistry is an extraordinary source for new medicines."Enveda's breakthrough technology combines artificial intelligence and nature, significantly accelerating time to market, reducing costs, and addressing some of today's biggest health challenges.They use machine learning to decode billions of years of evolutionary intelligence, creating a deep pipeline that positions the company at the forefront of drug discovery.Enveda is pioneering the "sequencer" for life chemistry, an AI-driven platform that combines metabolomics data with machine learning and high-throughput biological experiments to answer two fundamental questions about any natural sample on a large scale: (1) What are the molecules? (2) What do they do? In just four years, Enveda's platform has characterized the structure and function of more than one million natural compounds, creating the largest known dataset of natural products tailored for modern drug discovery workflows. As a result, Enveda’s drug development team can harness the billions of years of evolutionary intelligence encoded in the chemistry of nature at every stage and scale of drug discovery, uncover novel mechanisms of action, and deliver differentiated drugs faster than ever before in history.In October, Enveda received IND approval from the U.S. FDA for ENV-294, a novel, first-in-class oral anti-inflammatory drug targeting atopic dermatitis and other inflammatory conditions. ENV-294 subsequently entered Phase I clinical trials at the end of October as the first candidate compound discovered using the Enveda platform. ENV-294 demonstrates JAK inhibitor-like efficacy and IL4/IL13-like safety, targeting atopic dermatitis and other inflammatory diseases.Follow the official account below to see the world!
